BioCity Scotland-based compound management company BioAscent has launched ‘Compound Cloud’ – described by the company as ‘the Spotify of the drug discovery world’.
Organisations involved in the search for new drugs need a range of chemical compounds to test against their biological assays. In the past, these organisations were faced with either creating their own compounds, which is costly and time consuming, or buying fixed sets of compounds in large amounts, inevitably leading to wastage.
Compound Cloud enables customers to have control over the content and format of their compound library to fit their needs – eliminating wastage and reducing storage space by offering ‘just in time’ global delivery of pre-plated sets containing just enough compound for an assay.
BioAscent predicts that high demand for this service will increase turnover for this part of their company by 300 per cent over the next year, with three quarters of orders coming from overseas markets, including Europe, the US and Canada.
Simon MacKenzie, BioAscent’s CEO said: “Compound Cloud was created after gathering extensive feedback from our customers. It provides simple, rapid and flexible access to quality compound libraries for drug discovery. It will allow customers to have complete control over their compound library, using our library as if it were their own.”
Glenn Crocker, chief executive of BioCity Group added: “Around 35% of early stage drug discovery projects in both industry and academia fail at the hit stage due to the poor structural properties of the compounds found through biological testing, which means there is no value to progressing these any further. This can be hugely frustrating for all involved, after what can be years of biological work. Compound Cloud is an exciting development which will help improve companies’ chances of drug discovery success, which is good news not just for the companies but for healthcare in general.”